February 2018: The source guidance and definitions for statement 6 have been updated to ensure alignment with the updated NICE diagnostics guidance on self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system). In statement 3, the rationale and definition sections have been changed to include edoxaban as an option for anticoagulation to reflect NICE technology appraisal guidance on edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation.
Minor changes since publication
June 2021: Further information was added to bleeding risk score in the definitions section of statement 1.
April 2021: Source guideline recommendation numbers were updated throughout and definitions for statements 1 and 2 were amended in line with the updated NICE guideline on atrial fibrillation.